CDK4 and neoplasm: Not only may tumor cells at baseline express the high levels of dsRNA necessary to trigger the viral mimicry response, but this response can be enhanced further upon treatment with DNA-demethylating agents35, including the CDK4/6 inhibitor abemaciclib36.